|1.||Lipman, Jeffrey: 5 articles (01/2016 - 06/2012)|
|2.||Roberts, Jason A: 5 articles (01/2016 - 06/2012)|
|3.||Sakoulas, George: 5 articles (07/2015 - 07/2011)|
|4.||Jacobs, Frédérique: 5 articles (02/2013 - 11/2010)|
|5.||Acevedo, Juan: 4 articles (01/2015 - 05/2012)|
|6.||Fernández, Javier: 4 articles (01/2015 - 05/2012)|
|7.||Falagas, Matthew E: 3 articles (03/2015 - 08/2012)|
|8.||Vardakas, Konstantinos Z: 3 articles (03/2015 - 08/2012)|
|9.||Blanca, Miguel: 3 articles (01/2015 - 01/2011)|
|10.||Vincent, Jean-Louis: 3 articles (02/2013 - 11/2010)|
09/01/2015 - "Studies reporting MICs of β-lactams used for infection and clinical outcome were identified through a systematic literature search. "
01/01/2016 - "In the subgroup of patients who had respiratory infection, patients receiving β-lactams via prolonged infusion demonstrated significantly better 30 day survival when compared with intermittent-bolus patients [86.2% (25/29) versus 56.7% (17/30); P = 0.012]. "
12/01/2015 - "Enterobacter cloacae complex (ECC), an opportunistic pathogen causing numerous infections in hospitalized patients worldwide, is able to resist β-lactams mainly by producing the AmpC β-lactamase enzyme. "
09/01/2015 - "Our objective was to investigate whether the clinical outcomes of patients with invasive infections caused by Enterobacteriaceae treated with β-lactams were worse among those with a borderline susceptible MIC according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints than those with a lower MIC. "
09/01/2015 - "Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β-lactams: a systematic review and meta-analysis."
|2.||Cystic Fibrosis (Mucoviscidosis)
12/15/2012 - "Efficacy of β-lactams as single agents for treating severe pulmonary exacerbations during pregnancy in cystic fibrosis."
01/01/2012 - "Drug allergy to ß-lactams in cystic fibrosis patients is of importance. "
03/01/2015 - "Among several inhaled β-lactams, ceftazidime was used with varying success in the prevention and treatment of ventilator-associated pneumonia (VAP) and improved clinical outcomes in chronic Pseudomonas aeruginosa lower respiratory tract infections (LRTIs) in patients with cystic fibrosis (CF) or bronchiectasis. "
12/01/2014 - "In conclusion, VRE bacteremia was the most common BSI in allogeneic HSCT recipients, occurred primarily in neutropenic patients receiving broad-spectrum β-lactams and was associated with poor outcomes. "
08/01/2013 - "Answer: Klebsiella pneumoniae bacteremia showing filamentous forms and spheroplasts due to the presence of subinhibitory concentrations of β-lactams."
01/15/2016 - "In vitro laboratory and animal studies demonstrate a synergistic role for the combination of vancomycin and antistaphylococcal β-lactams for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. "
08/01/2015 - "The objective of this study was to determine risk factors for the development of resistance to β-lactams/β-lactamase inhibitors (βL/βLIs) and ertapenem among Bacteroides species bacteremia. "
07/01/2015 - "Efficacy and clinical outcomes in patients with VRE bacteremia who received at least 3 days of daptomycin with or without concomitant β-lactams were analyzed. "
01/01/2012 - "monocytogenes has a high level of innate resistance to the cephalosporin family of β-lactams frequently used to treat sepsis of unknown etiology. "
04/01/2011 - "Doses of hydrophilic agents such as β-lactams should be increased in the early stages of sepsis as the extravascular space increases. "
06/01/2012 - "2. β-Lactams are the most common antibiotic class used in critically ill sepsis patients because of their broad spectrum of activity and high tolerability. "
09/01/2011 - "Patients with shock or severe sepsis should probably receive combination therapy with β-lactams plus a macrolide due to its immunomodulatory effect."
04/01/2015 - "Policies commonly recommended dual therapy with aminoglycosides and β-lactams for abdominal sepsis [40/93 trusts (43%)] and undifferentiated severe sepsis [54/94 trusts (57%)]. "
07/01/2011 - "With proven Legionella pneumonia, a combination of β-lactams with a fluoroquinolone or a macrolide is beneficial. "
11/01/2014 - "Due to the emergence of extended-spectrum β-lactamase-producing Klebsiella pneumoniae (ESBL-Kpn) infections, the inoculum effect of ESBL-Kpn on β-lactams was studied in vitro and in vivo using an experimental model of pneumonia. "
03/01/2012 - "There were no significant differences in DSWI or all other categories of surgical site infections (SSIs) for antibiotic prophylaxis with β-lactams comprising a Gram-negative spectrum of coverage versus prophylaxis targeting Gram-positive bacteria, but the former led to a significantly lower rate of post-operative pneumonia (RR 0.68, 95% CI 0.51-0.90) and all-cause mortality (RR 0.66, 95% CI 0.47-0.92). "
09/01/2015 - "Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis."
03/01/2012 - "We assessed the in vitro susceptibility of Streptococcus pneumoniae isolates from patients with confirmed community-acquired pneumonia (CAP) to β-lactams, macrolides and fluoroquinolones and the association of non-susceptibility and resistance with serotypes/serogroups (STs/SGs), patient's risk factors and vaccination status. "
|3.||Anti-Bacterial Agents (Antibiotics)
|4.||Carbapenems (Carbapenem Antibiotics)
|5.||Cephalosporins (Cephalosporin Antibiotics)
|7.||imipenem drug combination cilastatin (Primaxin)
|2.||Complete Denture (Dentures, Complete)
|4.||Intensive Care (Surgical Intensive Care)
|5.||Length of Stay